No assignee for this patent application has been made.
News editors obtained the following quote from the background information supplied by the inventors: "Computed tomography (CT) is a powerful diagnostic tool based on X-ray attenuation that provides 3D or 4D images with spatial resolutions
"Contrast agents of nanometer-scale dimensions are emerging as powerful probes for in vivo imaging in medical and biological diagnostics (Hahn, M. A., et al., Nanoparticles as Contrast Agents for in-vivo Bioimaging: Current Status and Future Perspectives. Anal Bioanal. Chem. 2011, 399, 3-27). Iodinated organic molecules are the most universally accepted CT contrast agents used clinically. The high atomic number (Z) element in these agents (i.e., iodine) is typically covalently bound, which makes the agents relatively safe for use in humans. Methods to fabricate nano-scale contrast agents (NCAs) of iodinated molecules have focused on incorporating the molecules into nanoparticles using emulsions, liposomes, lipoproteins, and polymers. The methods have been applied in vivo with varying degrees of success. A common drawback of these iodinated NCAs is that it is often necessary to covalently modify a small-molecule contrast agent for incorporation into a nanoparticle. For example, the agent DTA was converted to an ester to be included into a suspension with a surfactant (
As a supplement to the background information on this patent application, VerticalNews correspondents also obtained the inventor's summary information for this patent application: "The invention provides co-crystals and salts of contrast agents associated with co-crystal formers (CCFs).
"One embodiment provides a co-crystal comprising: a) a contrast agent; and b) a co-crystal former.
"One embodiment provides a co-crystal or salt comprising: a) a contrast agent; and b) a co-crystal former comprising one or more N-aryl groups.
"One embodiment provides a pharmaceutical composition comprising a co-crystal or salt of the invention as described herein, and a pharmaceutically acceptable carrier.
"One embodiment provides a method to image a certain part of an mammal (e.g., a human) comprising administering a co-crystal or salt of the invention as described herein to the mammal and imaging the mammal.
"One embodiment provides the use of a co-crystal or salt of the invention as described herein as an imaging agent (e.g., a computed tomography imaging agent).
"One embodiment provides a method for preparing a co-crystal or salt of the invention as described herein comprising contacting a contrast agent with a co-crystal former.
"The co-crystals and salts of the invention may have one or more of the following beneficial properties such as improved solubility, enhanced distribution, decreased toxicity, lower clearance or higher loading of the contrast agent upon administration.
BRIEF DESCRIPTION OF THE FIGURES
"FIG. 1 shows the perspective view of DTA1 wherein DTA molecules assemble into dimers. The dimers propagate along the a-axis to yield 1D columns bridged by water tetramers.
"FIG. 2 shows the perspective of the X-ray crystal structure DTA2 wherein BPE molecules are oriented between DTA dimers (water molecules were omitted for clarity).
"FIG. 3 shows the X-ray structure of ATA1 viewed along the b-axis (water molecules were omitted for clarity).
"FIG. 4 shows the X-ray structure of IPA1 viewed along the c-axis to reveal a supramolecular ladder.
"FIG. 5 shows the perspective view of DTA3 wherein PHE molecules hydrogen bond to a 1D column of DTA molecules.
"FIG. 6A shows the perspective view of the four-component assembly that comprises ATA2 and FIG. 6B shows the layers of ATA and PHE viewed along the a-axis.
"FIGS. 7A and 7B show the X-ray structure of IPA2; FIG. 7A shows the three-component assemblies viewed along the b-axis and 7B shows the packing of zig-zag chains viewed along the c-axis.
"FIGS. 8A and 8B show the X-ray structure of ATA3; FIG. 8A shows the four-component assemblies viewed along the c-axis and FIG. 8B shows the layered arrangement of ATA and ACR molecules viewed along the a-axis.
"FIG. 9 shows the X-ray structure of IPA3 viewed along the a-axis to reveal a supramolecular ladder with BHT molecules serving as the rungs of the ladder.
"FIG. 10 shows the X-ray structure of DTA4 viewed along the a-axis, wherein, DTA and water molecules assemble into a channeled network that encapsulates stacked DDA molecules.
"FIG. 11 shows the perspective view of the 1D chains that comprise ATA4 (water molecules have been omitted for clarity)."
For additional information on this patent application, see: MacGillivray, Leonard R. Co-Crystals and Salts of Contrast Agents and Imaging. Filed
Keywords for this news article include: Patents, Nanoparticle, Nanotechnology, Supramolecular, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- U.S. Consumer Sentiment Falls in Early March
- Vybz Kartel Convicted of Murder
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- Keurig Adds Peet's coffee, Alters Starbucks deal
- Quiznos Files for Chapter 11
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Koch Brothers Step up Anti-Obamacare Campaign
- U.S. to Relinquish Gov't Control Over Internet
- Is Malaysian Airlines Flight 370 in Andaman Sea?